Barclays Rates uniQure (QURE) buy, $65 Price Target

Barclays Shifts Stance on uniQure N.V.

On June 18, 2026, Barclays analyst Eliana Merle took a fresh look at uniQure N.V., trading on the NasdaqGS under the ticker QURE. The firm raised its rating to a buy, assigning a price target of $65.00. This adjustment brings fresh attention to the biotechnology firm as it advances clinical trials for rare genetic disorders.

Market Standing and Moving Averages

The shares recently traded at a spot price of $48.26. That level sits well above the 50-day moving average of $40.20 and the 200-day moving average of $29.66. Over the past year, the stock has moved between a low of $8.73 and a high of $71.50, reflecting brisk movement in the biotech sector.

Wall Street Analyst Coverage

Other major financial firms have also adjusted their views on uniQure in recent months. On June 25, 2026, Mizuho maintained an outperform rating while raising its target to $68.00. A few days later on June 29, 2026, HC Wainwright & Co. maintained a buy rating and lifted its target to $80.00. Into the summer, Wolfe Research initiated coverage with an outperform rating and a $65.00 target on July 30, 2026, while Wells Fargo maintained an overweight rating and raised its target to $75.00. Later in the autumn, Goldman Sachs maintained a neutral rating with a $31.00 target on September 30, 2026. RBC Capital maintained an outperform rating with a $48.00 target on October 2, 2026. Finally, Barclays shifted its stance again later in the year, moving to an equal-weight rating with a $28.00 target on October 5, 2026. Overall, the stock currently holds a strong buy consensus with a mean price target of $61.46 derived from 12 analyst opinions.

Gene Therapy Pipeline Focus

uniQure N.V. builds gene therapy treatments for rare conditions from its headquarters in Amsterdam, Netherlands. Its portfolio includes HEMGENIX for hemophilia B, alongside early-stage candidates targeting Huntington's disease, epilepsy, ALS, and Fabry disease. Because the company is not currently profitable, it has no meaningful P/E ratio, though it reports revenue tied to its ongoing commercial and development efforts.

Looking Ahead for QURE

Investors will look toward the company's next earnings report on November 9, 2026, for further updates on clinical trial milestones and financial health. As the firm continues patient studies for its lead pipeline candidates, market watchers will track how well clinical progress aligns with these revised Wall Street expectations.